NAD+

II. What is this compound?

NAD+ exists in two forms — oxidized NAD+ and reduced NADH — together forming a redox pair essential for hundreds of enzymatic reactions. Structurally it is a dinucleotide: two nucleotides joined through their phosphate groups, with a molecular weight of approximately 663 daltons [3] PMID: 32573651 .

Unlike peptides, NAD+ is not encoded by genes or assembled on ribosomes. The body builds it through three distinct pathways: the salvage pathway (recycling nicotinamide via the enzyme NAMPT), the de novo pathway (building NAD+ from tryptophan through the kynurenine route), and the precursor pathway (consuming NMN or NR, which are converted to NAD+ inside cells) [4] PMID: 26785480 .

The salvage pathway handles the majority of NAD+ turnover in most tissues — which is why NAMPT, its rate-limiting enzyme, has become a research target in its own right: NAMPT activity declines with age, and that decline may explain why NAD+ pools shrink over time.

There's a practical catch: NAD+ cannot be taken directly as a supplement in meaningful amounts, because it degrades rapidly in the gut and bloodstream. So research has focused on precursors — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — that cells can absorb and convert into NAD+ through intracellular enzymatic steps [5] PMID: 27721479 .

III. How it works

The scientific fascination with NAD+ centers on three enzyme families that consume it as fuel — and whose output depends directly on how much NAD+ is left in the tank.

Sirtuins (SIRT1–7) are NAD+-dependent protein deacetylases: they remove acetyl groups from histones and other proteins, reshaping gene expression and protein function. SIRT1 regulates metabolic homeostasis, fat storage, and glucose metabolism; SIRT3, SIRT4, and SIRT5 operate inside mitochondria, controlling oxidative stress and energy production; SIRT6 influences DNA repair and telomere maintenance. In yeast, worms, and mice, sirtuin activation has extended lifespan under certain conditions — though whether that translates to humans remains an open question [6] PMID: 24786309 .

PARPs (poly(ADP-ribose) polymerases), especially PARP-1 and PARP-2, spend NAD+ building poly(ADP-ribose) chains at sites of DNA damage — molecular flags that recruit repair machinery to single-strand breaks. Every repair event consumes NAD+, and chronic damage — the kind that accumulates with age — can drain cellular pools substantially. Research suggests this PARP-mediated drain competes with sirtuins for the same NAD+ supply, creating a functional trade-off between DNA repair and metabolic regulation [7] PMID: 31065944 .

CD38, an NAD+-consuming glycohydrolase, is the third consumer — and its expression climbs with age. Studies indicate CD38 may be the primary driver of age-related NAD+ decline in certain tissues, degrading both NAD+ and its precursor NMN, which has turned CD38 inhibition into an active area of pharmacological research [8] PMID: 26785480 .

Put the three families together and you get what researchers describe as an NAD+ sink: as PARP and CD38 activity rises with age, sirtuins don't fail — their substrate simply gets consumed elsewhere first [9] PMID: 32573651 . The question that follows naturally: what happens when you refill the tank?

• Substrate for sirtuin family (SIRT1–7) protein deacetylases regulating metabolic homeostasis, stress response, and mitochondrial function
  PMID 24786309PMID 26785480
• Substrate for PARP-1/PARP-2 poly(ADP-ribose) polymerases mediating DNA damage sensing and single-strand break repair
  PMID 31065944PMID 32573651
• Substrate for CD38/CD157 glycohydrolases; CD38 activity increases with age and depletes cellular NAD+ pools
  PMID 26785480PMID 32573651
• Cofactor in mitochondrial oxidative phosphorylation (Complex I, NADH dehydrogenase) linking NAD+/NADH ratio to cellular bioenergetics
  PMID 26785480

IV. Research Findings

Start with metabolic health, where the clinical data run deepest. A randomized, double-blind trial administering 1000 mg/day of NR to obese adults for six weeks found increased skeletal muscle NAD+ metabolites, alongside modest improvements in body composition and sleeping metabolic rate [10] PMID: 32320006 . A separate dose-response study found NR at 300 mg/day raised whole-blood NAD+ by 48% — and at 1000 mg/day by 139%, meaning blood NAD+ more than doubled over eight weeks in overweight adults [11] PMID: 29184669 .

Anti-aging and longevity evidence remains primarily preclinical. In aged mice, NMN supplementation restored NAD+ levels to those of younger animals while improving insulin sensitivity, mitochondrial function, and markers of inflammation [12] PMID: 24786309 — findings that fueled the hypothesis that replenishing NAD+ could slow or partially reverse certain biological aging processes.

DNA repair capacity ties directly to NAD+ availability. Reduced intracellular NAD+ suppresses recruitment of XRCC1, a key DNA repair protein, to sites of genomic damage; supplementing with NAD+ or NMN restored repair capacity in cell culture models [13] PMID: 31065944 .

Cognitive function is the newest frontier. Preclinical models suggest declining brain NAD+ contributes to neurodegeneration, and early clinical trials are testing whether NR supplementation can improve cognition in Alzheimer's and Parkinson's disease patients [14] PMID: 31577933 .

Human performance data followed. A 2024 randomized trial of NMN in 80 middle-aged adults found significant increases in blood NAD+ at 30 and 60 days across all dose groups (300, 600, and 900 mg/day) versus placebo — and participants didn't just post better lab numbers: physical performance on the six-minute walking test improved too [15] PMID: 36482258 .

• anti-aging preclinical and early clinical
  PMID 24786309PMID 26785480
• metabolic-health clinical
  PMID 32320006PMID 36482258
• dna-repair preclinical
  PMID 31065944PMID 32573651
• cognitive-function preclinical and early clinical
  PMID 31577933

V. Dosage Context Explained

Published human dosing data come from a growing set of randomized controlled trials, primarily using oral NR and NMN.

Nicotinamide riboside (NR) has been tested at 100–2000 mg/day. The most cited dose-response study found 300 mg/day effective for meaningful NAD+ elevation, with 1000 mg/day producing that 139% increase over eight weeks [16] PMID: 29184669 . A safety-focused trial in 120 adults aged 60–80 confirmed that NR combined with pterostilbene was well-tolerated, delivering NAD+ increases of 40% (standard dose) to 90% (double dose) after four weeks [17] PMID: 29184669 .

Nicotinamide mononucleotide (NMN) has been studied at 250–900 mg/day. A multicenter trial in 80 middle-aged adults showed significant NAD+ elevation at every tested dose, with 900 mg/day producing the largest effect [18] PMID: 36482258 . Chronic supplementation at 250 mg/day for 12 weeks in healthy older men proved safe and well-tolerated, significantly increasing blood NAD+ and related metabolites.

One boundary frames all of it: these figures come exclusively from research settings, and no regulatory agency has established approved dosing guidelines for humans. Optimal dose, duration, and long-term safety remain open questions — which is exactly why the safety ledger deserves its own close look.

• Administration Routes

  oral (nicotinamide riboside)

  Range

  100–2000 mg/day

  randomized controlled trials in healthy adults; dose-dependent NAD+ elevation (100 mg = +10%, 300 mg = +48%, 1000 mg = +139% at 8 weeks)

  PMID 29184669PMID 32320006
• Administration Routes

  oral (NMN)

  Range

  250–900 mg/day

  placebo-controlled RCTs in middle-aged and older adults; significant blood NAD+ elevation at 30–60 days

  PMID 36482258

VI. Side Effects: Research Context

NAD+ precursors bring one of the cleaner safety ledgers in supplement research. Trials administering NR at up to 2000 mg/day for 12 weeks reported no serious adverse events [19] PMID: 29184669 ; mild gastrointestinal discomfort has surfaced anecdotally at higher doses. Nicotinamide — the simplest precursor — can cause flushing at high doses, a well-characterized, dose-dependent vasodilatory response driven by prostaglandins, though NR and NMN don't typically produce it.

Two cautions deserve honest airtime. First, tumor metabolism: cancer cells often upregulate NAD+ biosynthesis to fuel rapid proliferation, and while no clinical evidence links precursor supplementation to accelerated tumor growth, the mechanistic plausibility warrants caution in individuals with active malignancies [20] PMID: 32573651 . Second, long-term data beyond 12 weeks remain limited — the absence of severe adverse events reflects limited surveillance, not proven safety.

Neither caution closes the door. Larger cohorts, longer durations, and post-marketing surveillance are steadily filling the gaps — and the regulatory picture below shows how differently agencies weigh what's known so far.

• mild gastrointestinal discomfort at higher doses (anecdotal)
• flushing with nicotinamide at high doses
• no serious adverse events reported in clinical trials up to 2000 mg/day NR for 12 weeks

VII. Frequently Asked Questions